GTx (GTXI) Receives News Sentiment Rating of 0.10

News articles about GTx (NASDAQ:GTXI) have trended somewhat positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a unit of Accern, rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. GTx earned a news impact score of 0.10 on AlphaOne’s scale. AlphaOne also gave news stories about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have effected AlphaOne’s analysis:

Insider Buying and Selling by Quarter for GTx (NASDAQ:GTXI)

Separately, ValuEngine raised shares of GTx from a “strong sell” rating to a “sell” rating in a research report on Tuesday.

GTx (GTXI) traded down 3.76% during mid-day trading on Friday, hitting $4.61. 433,336 shares of the company traded hands. GTx has a one year low of $2.73 and a one year high of $11.19. The company’s 50-day moving average is $4.21 and its 200-day moving average is $4.85. The stock’s market capitalization is $73.95 million.

GTx (NASDAQ:GTXI) last issued its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.39) EPS for the quarter. Analysts predict that GTx will post ($1.16) EPS for the current year.

WARNING: This report was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at

About GTx

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with's FREE daily email newsletter.

Leave a Reply